生物醫藥產業對人類健康福祉影響甚鉅，同時也屬於技術、資本密集、開發期長、風險偏高的產業，在新藥開發的歷程中，臨床試驗是開發中藥品自「試驗階段」邁向「市場階段」的絕對關鍵過程，其重要性不言而喻。對藥廠而言，臨床試驗若能有效率地被執行，一方面可縮短試驗時間減少花費；另一方面則是搶得先機佔據市場，及早實現獲利。因應臨床試驗重要且繁複需求的臨床試驗服務公司（Contract Research Organization, CRO）便應蘊而生。 CRO產業在美國的發展已逾40年，在奠基於過去的競爭基礎之外，其CRO產業已朝向「便利性」與「客製化」等利基市場佈局，以滿足新的顧客價值主張，並創新商業模式，追求新的成長機會。本研究在介紹美國CRO之產業市場營運模式之外，也以個案分析方式，自國內CRO公司與藥廠/生技公司的互動、合作，探討CRO的營運模式是否符合客戶需求，並嘗試以<白地策略>書中四個核心市場要素：顧客價值主張、利潤公式、關鍵流程與關鍵資源，思索CRO公司應如何經營市場白地。希望借鏡國外CRO公司的演進，反饋予國內CRO產業的未來發展及策略調整參考。 / Bio-pharmaceutical industry on human health well-being highly influential, but also a industry of technical, capital intensive, long development periods, and high risk. Among the course of drug development, clinical trials are absolute the key to the process, and advance the development process from the pilot phase to the market phase. For pharmaceutical companies, if the clinical trial can be executed efficiently, they can shorten the test time and spending; seize the market in advance, and reap profits as soon as possible. In response to the important and complex clinical trial requirements, the Contract Research Organization (CRO) prospers and takes advantage of a favorable situation. The evolvement of the CRO industry in US is more than 40 years. In the foundation base in the past, the CRO industry has been towards convenience and customization and other niche market distribution, to meet new customer value propositions, innovative business models and pursue new growth opportunities. In this thesis, the author not only introduces the CRO’s business models in US, but also explores the CRO’s business models in Taiwan by way of case studies. Through the interaction and cooperation between domestic pharmaceutical companies and CROs, the author wants to find out if the business models of CROs are in line with customer needs. The author also wants to quest if the CROs can learn how to manage and operate a white space which the CROs hope to seize by way of the book Seizing the White Space lists four fundamental building blocks including customer value proposition, profit formula, key resources, and key processes that make a company business model works. The domestic CROs can adjust their strategy and business model for fitting customer’s value proposition.

No description available.

Introdução. A intervenção coronária percutânea (ICP) é um dos tratamentos para pacientes com doença arterial coronária (DAC). Essa intervenção deve ser acompanhada de outras medidas terapêuticas com o intuito de reduzir as incapacidades e o risco de novos eventos coronários; de controlar a progressão da doença; e de melhorar a qualidade de vida. Essas medidas compreendem a prevenção secundária da DAC e estão, principalmente, relacionadas às mudanças no estilo de vida para o manejo de fatores de risco para DAC. O contato por telefone tem sido utilizado por profissionais da área da saúde para o seguimento do paciente e da família no cuidado com diversas condições crônicas, incluindo a DAC. Objetivo. Desenvolver, implementar e avaliar um programa educativo com seguimento por telefone, durante o período de quatro meses após a alta hospitalar, para pacientes submetidos à ICP com o objetivo de melhorar o estado de saúde percebido, a autoeficácia, a adesão aos medicamentos e o estado emocional desses pacientes, bem como comparar desfechos do Programa Educativo com os de serviços de rotina hospitalar. Método. Ensaio clínico controlado e aleatorizado, realizado no Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto. A amostra deste estudo foi constituída pelos pacientes submetidos à primeira ICP, entre agosto de 2011 e junho de 2012. Os participantes foram aleatorizados para o Programa Educativo com Seguimento por Telefone (grupo intervenção [GI]: 30 participantes) ou cuidado conforme a rotina da instituição (grupo controle [GC]: 30 participantes). O referencial teórico que fundamentou o Programa Educativo aplicado neste estudo foi o construto de autoeficácia, presente na Teoria Social Cognitiva de Albert Bandura. O desfecho principal foi o estado de saúde percebido, avaliado pelo Medical Outcomes Survey 36- Item Short Form (SF-36), e os desfechos secundários foram a autoeficácia avaliada pela Escala de Autoeficácia Geral Percebida, a adesão aos medicamentos por meio do instrumento Medida de Adesão aos Tratamentos (MAT) e o estado emocional (ansiedade e depressão) avaliado pela Escala Hospitalar de Ansiedade e Depressão (HADS). Os desfechos foram avaliados antes do procedimento (T0) e seis meses após a ICP (T1). A análise foi por análise descritiva, análise de variância para medidas repetidas, teste de Qui-quadrado e risco relativo com intervalo de confiança de 95%. O nível de significância foi de 0,05. Este ensaio clínico foi registrado sob o número NCT01341093. Resultados. Na avaliação do estado de saúde percebido, com um nível de significância de 0,05, nenhuma interação (tempo e grupo) ou grupo foi estaticamente significante, mas houve interação entre tempo e grupo com valores de nível de significância entre 0,05 e 0,10 no Sumário do Componente Mental (p=0,08) e no domínio Aspectos Emocionais (p=0,07) e melhora no domínio Aspectos Sociais no GI (p=0,10). Na avaliação da autoeficácia, não houve diferenças entre os grupos ou tempos. Houve alta percentagem de participantes que relataram adesão aos medicamentos nos tempos T0 e T1, nos dois grupos (mais de 90% inicial e no seguimento). Na avaliação da ansiedade, seis meses após a ICP, houve aumento de não-caso de ansiedade no GI e diminuição no GC, e a associação entre as variáveis foi estatisticamente significante (p=0,04). Ao final do seguimento, o risco relativo do GI de ser não-caso de ansiedade foi de 1,6 (intervalo de confiança [IC] de 95%=1,0 a 2,4) quando comparado com o GC. Em relação à depressão, não houve evidência de diferenças no percentual de pacientes não- caso de depressão entre os grupos (GI e GC), tanto na internação como no seguimento. Ao final do seguimento, o risco relativo do GI de ser não-caso de depressão foi de 0,8 (intervalo de confiança [IC] de 95%=0,6 a 1,1), quando comparado com o GC. Conclusão. O Programa Educativo com Seguimento por Telefone é uma intervenção promissora para melhorar o estado de saúde percebido e para reduzir a ansiedade de pacientes submetidos à ICP. Pode ser necessário aperfeiçoar a intervenção para que haja efeitos na autoeficácia e na depressão. Os instrumentos para medidas de autoeficácia e de adesão aos medicamentos precisam ser melhorados / Introduction. Percutaneous coronary intervention (PCI) is one of the treatments available for coronary artery disease (CAD) patients. This intervention should be accompanied by other therapeutic interventions with the aim of reducing disabilities and the risk of new coronary events, controlling the progression of the disease, and improving the quality of life. These interventions comprise the secondary prevention of CAD and are mainly related to lifestyle changes, aiming to manage risk factors for CAD. Health professionals have used telephone follow-up to monitor patients and families in the delivery of care to different chronic conditions, including CAD. Objective. To develop, to implement and to assess an educational program with telephone follow-up, during four months after hospital discharge, for patients submitted to PCI, with the aim of improving the perceived health status, self-efficacy, medication adherence and emotional status of these patients, as well as to compare outcomes of the Educational Program with routine hospital services. Method. Randomized controlled clinical trial, developed at the Ribeirão Preto Medical School Hospital das Clínicas, Brazil. The study sample included patients who had been submitted to their first PCI between August 2011 and June 2012. The participants were randomly assigned to the Educational Program with Telephone Follow-up (intervention group [IG]: 30 participants) and routine care (control group [CG]: 30 participants). The theoretical framework that supported the Educational Program applied in this study was the self-efficacy construct in Albert Bandura\'s Social Cognitive Theory. The main outcome was the perceived health status, assessed using the Medical Outcomes Survey 36- Item Short Form (SF-36); and the secondary outcomes were self-efficacy, assessed using the Perceived General Self-Efficacy Scale; medication adherence, assessed using the Medida de Adesão ao Tratamento (MAT); and the emotional status (anxiety and depression), assessed using the Hospital Anxiety and Depression Scale (HADS). The outcomes were evaluated before the procedure (T0) and six months after the PCI (T1). Descriptive analysis was applied, as well as variance analysis for repeated measures, the chi-square test and relative risk, with the confidence interval set at 95%. Significance was set at 0.05. This clinical trial was registered under number NCT01341093. Results. In the assessment of the perceived health status, with significance set at 0.05, no interaction (time and group) or group was statistically significant, but interaction between time and group was verified, with significance levels ranging between 0.05 and 0.10 in the Mental Component Summary (p=0.08) and in the Emotional Aspects domain (p=0.07); as well as improvement in the Social Aspects domain for the IG (p=0.10). In the assessment of self-efficacy, no differences were found between the groups or times. Many participants indicated medication adherence at T0 and T1 in the two groups (more than 90% initially and during the follow-up). In the assessment of anxiety levels six months after the PCI, the number of non-cases of anxiety increased in IG and dropped in CG, with a statistically significant association between the variables (p=0.04). At the end of the monitoring, the relative risk of being a non-case of anxiety in IG corresponded to 1.6 (95% confidence interval [CI]=1.0 - 2.4) when compared to CG. As regards depression, no evidence was found of differences in the percentage of patients non-case of depression between the groups (IG and CG), neither during hospitalization nor during follow-up. At the end of the follow-up, the relative risk of IG being a non-case of depression corresponded to 0.8 (95% confidence interval [CI]= 0.6 - 1.1) when compared to CG. Conclusion. The Educational Program with Telephone Follow-up is a promising intervention to improve the perceived health status and reduce the anxiety of patients submitted to PCI. The intervention may need further development to influence self-efficacy and depression. Self-efficacy and medication adherence instruments need improvements

INTRODUÇÃO: A Moléstia de Dupuytren (MD) é uma doença crônica progressiva fibroproliferativa caracterizada por contraturas em flexão dos dedos. A origem deste processo está na proliferação de miofibroblastos e na síntese de matriz extracelular. Diversas técnicas já foram descritas no tratamento da MD. A falta de uma técnica capaz de associar altas taxas de sucesso com baixos índices de complicações e recidivas estimulou a procura por novas técnicas. Acredita-se que a propriedade totipotente das células-tronco presentes no tecido adiposo seria capaz de atuar na proliferação e na diferenciação dos fibroblastos em miofibroblastos, interrompendo a formação da fibrose e consequentemente a progressão da deformidade dos dedos. OBJETIVO: O objetivo primário deste estudo foi avaliar o efeito do enxerto de gordura, rico em células-tronco, nos pacientes com MD, submetidos a fasciectomia parcial aberta, por meio de avaliação funcional e goniométrica, e comparar com a técnica convencional (sem adição de enxerto de gordura). MÉTODO: Dois grupos totalizando 45 pacientes (24 pacientes no Grupo Controle e 21 no Grupo com gordura) foram operados pela técnica da fasciectomia parcial aberta. No Grupo controle era realizada apenas a fasciectomia parcial aberta. No Grupo com gordura, era realizada a fasciectomia parcial aberta e injetado, no local da corda ressecada, o enxerto de gordura, após o processamento do lipoaspirado de adipócitos proposto por Coleman (2006). O estudo foi prospectivo, randomizado e terapêutico. Os desfechos foram avaliados pela medida goniométrica do Déficit de Extensão Passiva Total (DEPT) e pelo escore funcional Brief Michigan Hand Questionnaire (BMHQ). As avaliações eram feitas no pré-operatório, com 6 semanas, 6 meses, 1 ano e 2 anos de seguimento. RESULTADOS: Na comparação com 6 semanas de pós-operatório, houve um aumento significativo da dor no Grupo com Gordura [mediana 2 ± 2,82 versus 0 ± 1,86 no grupo Controle (p=0,045)]. Os resultados do DEPT, não mostraram diferença significativa entre os grupos. Observamos piores resultados do escore funcional BMHQ com 6 meses e 1 ano de pós-operatório no Grupo com gordura (p=0,040 e p=0,047, respectivamente). Observamos ainda 9 casos (43%) de complicações no Grupo com gordura e 2 (8%) no Grupo Controle (p=0,019). CONCLUSÃO: O uso do enxerto de gordura associado à fasciectomia parcial aberta promoveu piores resultados funcionais comparado com a fasciectomia parcial aberta convencional, no curto prazo (um ano de seguimento pós-operatório). No entanto, resta a dúvida de qual seriam os resultados a longo prazo e, se as células-tronco, presentes no enxerto de gordura, poderiam interferir na recidiva da doença futuramente / BACKGROUND: Dupuytren\'s disease (DD) is a progressive chronic fibroproliferative disease characterized by flexion contractures of the fingers. The origin of this process is the proliferation of myofibroblasts and extra-cellular matrix synthesis. Several techniques have been described to treat the DD. The lack of a technique capable to associate high success rates with low rates of complications and recurrence stimulated the search for new techniques. It is believed that the totipotent property of the adipose-derived stem cells present in the processed lipoaspirate tissue would be able to inhibit the proliferation and differentiation of fibroblasts in myofibroblasts, interrupting the formation of fibrosis and consequently the progression of finger deformity. The primary objective of this study was to evaluate the effect of adipose-derived stem cells in patients with DD who underwent to open limited fasciectomy and compare with the conventional technique of limited fasciectomy. METHODS: A total of 45 patients were assigned in two groups in a single blind, prospective, randomized, controlled trial. All the patients were treated by the limited fasciectomy technique. In the control group (24 patients), only limited fasciectomy was performed. In the study group (21 patients), after the limited fasciectomy procedure, autologous lipoaspirate was injected at the site of the resected cord. Outcomes were assessed by the Total Passive Extension Deficit (TPED) and by the Brief Michigan Hand Questionnaire (BMHQ) functional score. The evaluations were performed by occupational therapists in the preoperative and at 6 weeks, 6 months, 1 year and 2 years. RESULTS: The study group presented higher rates of pain at 6 weeks postoperative (median 2 ± 2,82 versus 0 ± 1,86 on control group, p=0,045). TPED showed no significant differences between groups. BMHQ score, at 6 months and 1 year after surgery, were significantly inferior in the study group (p=0,040 e p=0,047, respectively). Patients in the study group had higher incidence of complications (9 patients, 43% versus 2, 8% in the control group, p=0,019). CONCLUSIONS: The autologous lipoaspirate associated to limited fasciectomy demonstrates inferior results regarding to functional score and pain compared to conventional limited fasciectomy, in short-term. Further long-term analysis is required to observe the effect of adipose-derived stem cells in the recurrences rates

A tendência de globalização dos ensaios clínicos, observada nos últimos anos, trouxe à tona questões antes não discutidas como a continuidade do tratamento com os medicamentos em investigação, após a conclusão da pesquisa. A inclusão de países em desenvolvimento nesses estudos traz consigo a preocupação com a vulnerabilidade dos participantes da pesquisa. No Brasil, há cerca de cinco anos, os Comitês de Ética em Pesquisa, CEP, e, particularmente, a Comissão Nacional de Ética em Pesquisa, CONEP, passaram a solicitar a manutenção do fornecimento do(s) medicamento(s) do estudo após sua finalização. Embora baseada nos principais documentos éticos que norteiam a pesquisa clínica, essa solicitação apresenta dificuldades práticas para implantação, principalmente no caso de doenças crônicas. O objetivo deste trabalho foi identificar as questões envolvidas na continuidade do fornecimento de medicamentos após a conclusão de ensaio clínico e analisar a perspectiva de atores que compõem o cenário da pesquisa clínica nacional. Questionários e respectivos Termos de Consentimento Livre e Esclarecidos, TCLE, foram enviados por correioeletrônico, entre outubro de 2009 e janeiro de 2010, a membros de CEPs (todos os CEPs credenciados pela CONEP naquela data), pesquisadores (em duas áreas terapêuticas, HIV/AIDS e Diabetes mellitus) e patrocinadores. Aos pesquisadores foi solicitado que aplicassem o questionário a seus pacientes de pesquisa. A taxa de resposta dos CEPs foi de 20,7% (124 responderam, de 599 questionários enviados), 20% para os pesquisadores (58 de 290) e 45,3% para os patrocinadores (24 de 53). Cinquenta e quatro pacientes convidados por seus médicos responderam. Com relação à informação contida no TCLE, o item menos informado é relativo a como obter o medicamento após o estudo, para todos os grupos pesquisados. Com relação à motivação dos pacientes ao participar de uma pesquisa, 96,2% dos pacientes responderam como \"muito importante\", na decisão, a busca de melhores cuidados médicos e atenção à própria saúde, e 94,2% o fato de colaborar para o desenvolvimento da ciência (altruísmo). Entretanto, os demais grupos entrevistados não pensam da mesma forma: para eles, a maior motivação dos pacientes, ao participar de pesquisas clínicas, é a busca de melhores cuidados médicos e atenção à sua saúde, seguido da busca pelo acesso a alternativas de tratamento para sua doença. Ao serem perguntados sobre quem deveria receber o medicamento em investigação após o estudo, os pacientes responderam que todas as pessoas deveriam receber o medicamento após o estudo (60,4%); entre os pesquisadores, a maior parte (43,1%) respondeu que o medicamento deveria ser fornecido às pessoas participantes do estudo e 39,7% deles responderam que o medicamento deveria ser fornecido às pessoas que se beneficiariam do medicamento em estudo. Já os representantes de CEP concordaram com os pacientes que todas as pessoas deveriam receber o medicamento, mas em proporção bem menor (35,3%). Os patrocinadores opinaram que o medicamento do estudo deveria ser fornecido aos participantes da pesquisa que dele se beneficiariam (50%). Houve consenso entre os grupos em que, havendo a continuidade do tratamento, este deveria ser fornecido pelo patrocinador e de forma gratuita. Ao responder a questão relativa a quanto tempo deveria o medicamento ser fornecido, pesquisadores e patrocinadores consideraram que o medicamento deveria ser fornecido até estar disponível na rede pública, enquanto que os membros de CEP, opinaram que isso deveria acontecer durante o período que o paciente fosse beneficiado. Os pacientes responderam que o benefício deveria ser mantido pela vida toda. Devido às várias limitações deste estudo (representatividade da amostra, população restrita a usuários da Internet), seus resultados podem não ser generalizados, mas podem contribuir para a discussão do tema, ao analisar os pontos de vista de vários atores do cenário da pesquisa clínica nacional. / The recent trend of globalization of clinical trials, observed in the last years, raised some non-previously discussed issues, such as the continuity of treatment after the conclusion of the study. The inclusion of developing countries in these trials brings together the concern with the participants\' vulnerability. In Brazil, about 5 years ago, the Ethics Committees (EC) and the National Commission of Ethics in Research (so called CONEP) started requiring the access to study medication after the trial ends. Even being based on the main documents related to ethics and research, some practical issues make this requirement difficult to implement, mainly in the arena of chronic diseases. The goal of this research was to identify the questions related to continuing the supply of the investigational medicine and analyze the perspective of all stakeholders involved in clinical research. Questionnaires and informed consents were sent through e-mail, between Oct 2009 and Jan 2010, to EC members (all ECs mentioned at CONEP site at that moment), clinical investigators (in two therapeutical areas, HIV/AIDS and Diabetes) and sponsors. We also asked the clinical investigators to submit the questionnaire (in paper) to their patients who already participated in clinical research. The response rate in each group was: 20.7% in EC members\' group (599 questionnaires sent, 124 replied), 20% in clinical investigators\' group (58 of 290) and 45.3% in sponsors\' group (24 of 53). Fifty four patients answered the questionnaire through their doctors. Regarding to the information displaced in the informed consent, the item less informed, according to all groups, was related to how to obtain the study medication after the conclusion of the trial. Concerning the motivation of patients which made them accept to participate in a clinical trial, 96.2% of patients answered as \"very important\" to obtain better health care and attention and 94.2% mentioned also as \"very important\" the possibility to collaborate with the progress of the science (altruism). However, among the other groups, the responses were different: for them, the major motivation for the patients would be to have access to better health care and attention (similar to patients) and search for access to treatment alternatives for their diseases. When asked to whom should be given the study medication after the trial, the patients answered that all patients should receive it (60.4%); for the clinical investigators, 43.1% believe that the medication should be given to the participants of the study and 39.7% to the subjects who participated and benefited from the study treatment. The EC members agreed (but to a lesser degree, 35.3%) with the patients that all individuals with the disease should receive the medication after the trial. For 50% of the sponsors, the study medication should be assured to the participants who had benefit from the treatment. In the case of need of access extension after the trial, a consensus could be observed among all groups, concerning to whom should provide the medication (the sponsor) and how (completely free). One question addressed the issue of how long the treatment should be assured after the trial: clinical investigators and sponsors replied that the medication should be kept until be available in the public health sector; the EC members thought it should be furnished while the patient keeps the benefit. The patients answered that the benefit should be assured for all life. Due to the several limitations of this research (such as the sample representativeness, population restrict to internet users), their results can\'t be generalized; however, the data can contribute to the discussion of this very complex topic through analyzing the views of the several stakeholders of the scenario of clinical research in Brazil.

O presente estudo destinou-se a avaliar se os resultados clínicos iniciais da viscossuplementação poderiam ser melhorados com a adição de corticosteróide. As injeções intra-articulares são usadas há muitos anos no tratamento da osteoartrite dos joelhos, principalmente com suspensões cristalinas de corticosteróides. A viscossuplementação é uma intervenção relativamente nova, atualmente recomendada no tratamento da osteoartrite. Trata-se da injeção de ácido hialurônico exógeno em articulações diartrodiais, visando, além de restaurar as propriedades reológicas do líquido sinovial, efeitos modificadores da doença osteoartrite. Revisões sistemáticas mostram que a melhora clínica ocorre em duas a cinco semanas após a viscossuplementação. Comparando-se a viscossuplementação com a injeção intraarticular com corticosteróides, dados recentes sugerem maior eficiência no alívio da dor nas quatro primeiras semanas após a infiltração com corticosteróides, similaridade dos procedimentos ao redor da quarta semana e melhores resultados com a viscossuplementação após a oitava semana. Este inicio de ação mais tardio, associado a relatos de sinovite reacional após a viscossuplementação podem desencorajar médicos e pacientes ao uso desta modalidade de tratamento. No presente estudo foram avaliados 104 pacientes em tratamento para osteoartrite do joelho no grupo de doenças osteometabólicas do Instituto de Ortopedia do Hospital das Clínicas da FMUSP. Os pacientes foram randomizados em dois grupos. Um dos grupos foi denominado VS e recebeu uma única injeção intra-articular de 6ml de Hylan GF-20 (Synvisc One®-Genzyme) no joelho estudado. O segundo grupo foi denominado VS+T e recebeu uma injeção intra-articular de 6ml de Hylan GF-20 (Synvisc One®-Genzyme) mais 1ml (20mg) de Hexacetonido de Triancinolona (Triancil®-Apsen). Foram aplicados a escala visual analógica de dor (EVA) e os questionários de WOMAC e Lequesne uma semana antes da injeção e após uma, quatro, 12 e 24 semanas. Os dois grupos com 52 pacientes cada eram homogêneos. Na primeira semana, o WOMAC e a EVA apresentaram melhores resultados no Grupo VS+T (p < 0,01) em relação ao Grupo VS. Na quarta semana não houve diferença entre os grupos. Ambos apresentaram resultados similares nas semanas 12 e 24. Concluiu-se que a adição de hexacetonido de triancinolona melhorou os resultados clínicos da viscossuplementação no curto prazo, sem interferir nos resultados a longo prazo ou na incidência de efeitos adversos / The present study aims to assess if the initial results of viscosupplementation can be improved by the addition of corticosteroid. Intraarticular injections have been used for many years to treat arthritis and other painful articular disorders, mainly using long-lasting crystalline corticosteroid suspensions. Viscosupplementation is a relatively new intervention that is now widely used and recommended for the treatment of knee osteoarthritis. It is comprised of the injection of exogenous hyaluronic acid in diarthrodial joints, in order to restore the rheological properties of synovial fluid and also to promote osteoarthritis disease-modifying effects. Several placebo-controlled studies reported that clinical improvement began only within two to five weeks after viscosupplementation. When comparing viscosupplementation versus intraarticular injection of corticosteroid, recent data suggest that from baseline to week four, intraarticular steroid were more effective for pain relief. By the fourth week, however, both provided similar relief, but beyond the eighth week, hyaluronic acid provided greater pain reduction. The mechanism of action of hyaluronic acid, with delayed onset of pain/functional improvement, combined with reports of reactional sinovitis may discourage physicians and patients regarding this treatment modality. The present study evaluated 104 patients receiving usual care for knee osteoarthritis at the University of São Paulo Medical Center. Patients were randomized to receive either a single intra-articular injection of 6ml of Hylan GF-20 (Synvisc One®-Genzyme) (Group VS) or a single intra-articular injection of 6ml of Hylan GF-20 (Synvisc One®-Genzyme) plus 1ml (20mg) of Triamcinolone Hexacetonide (Triancil®-Apsen) (Group VS+T). VAS, WOMAC and Lequesne questionnaires were applied one week prior the injection, and after one, four, 12 and 24 weeks. The two groups with 52 patients each were homogeneous. At week one, WOMAC and VAS showed better results for Group VS+T compared to Group VS (p < 0,05). At week four the scores did not show statistically significant differences. The groups showed similar results at weeks 12 and 24. In conclusion, the addition of triamcinolone improved first-week symptom and functional scores of viscosupplementation, but not beyond. It did not seem to alter the likelihood of adverse effects

Background Primary radiochemotherapy with photons is the standard treatment for locally advanced-stage non-small cell lung cancer (NSCLC) patients. Acute radiation-induced side effects such as oesophagitis and radiation pneumonitis limit patients’ quality of life, and the latter can be potentially life-threatening. Due to its distinct physical characteristics, proton therapy enables better sparing of normal tissues, which is supposed to translate into a reduction of radiation-induced side effects. Methods/design This is a single-centre, prospective, randomised controlled, phase II clinical trial to compare photon to proton radiotherapy up to 66 Gy (RBE) with concomitant standard chemotherapy in patients with locally advanced-stage NSCLC. Patients will be allocated in a 1:1 ratio to photon or proton therapy, and treatment will be delivered slightly accelerated with six fractions of 2 Gy (RBE) per week. Discussion The overall aim of the study is to show a decrease of early and intermediate radiation-induced toxicity using proton therapy. For the primary endpoint of the study we postulate a decrease of radiation-induced side effects (oesophagitis and pneumonitis grade II or higher) from 39 to 12%. Secondary endpoints are locoregional and distant failure, overall survival and late side effects. Trial registration Registered at ClinicalTrials.gov with Identifier NCT02731001 on 1 April 2016.

Compte tenu des risques non-négligeables liés à la prise en charge des personnes souffrant de maladie d'Alzheimer sur la santé globale et le bien-être des aidants informels, l'OMS recommande fortement la mise en place d'interventions à leur égard. Bien que les programmes en ligne représentent un outil prometteur pour ces aidants surchargés, peu de recherches ont été menées sur leur conception et leur efficacité. Le but de cette thèse de doctorat était de contribuer à la connaissance et la compréhension des processus du développement et d'évaluation de ces interventions. Pour cela, quarante-neuf participants (12 professionnels de la santé, 6 aidants et 31 personnes âgées) ont participé au processus itératif de conception du programme Diapason centrée sur l'utilisateur. La dernière version a été évaluée dans un essai clinique randomisé, basé sur des méthodes de recherche mixtes. Quarante-neuf aidants informels de personnes atteintes de maladie d'Alzheimer ont été randomisés soit dans le groupe expérimental (n = 25) ou soit dans le groupe de contrôle (n = 24). Bien que les résultats portant sur l'efficacité du programme ne soient pas concluants, les personnes du groupe expérimental ont significativement augmenté leurs niveaux de connaissance de la maladie (p = 0,008 d' = 0,79). Par ailleurs, l'analyse qualitative a montré que les enfants des patients avaient donné un avis plus favorable que les épouses sur l'utilité du programme. Les résultats de ces travaux offrent des perspectives prometteuses pour ce type d'interventions, en particulier quand elles sont personnalisables et centrées sur les besoins des aidants. Ce travail permet de mieux appréhender les spécificités méthodologiques liées au développement et à l'évaluation des interventions des aidants. / Given the important consequences of caregiving on the overall health and wellbeing of informal caregivers, the WHO strongly recommends interventions for them. Although Internet-based programs represent a promising tool for overburdened caregivers, little research has been conducted about their design and efficacy. The purpose of this PhD dissertation was to contribute to the knowledge and understanding of the development, evaluation, and implementation process of these programs. For this purpose, we involved forty-nine participants (12 healthcare professionals, 6 caregivers, and 31 healthy older-adults) in the iterative user-centered design process for the development of the Diapason program. The latest version of this program was evaluated in a randomized clinical trial, based on mixed methods research. Forty-nine informal caregivers of persons with Alzheimer's disease were randomly assigned to the experimental (n=25) or control group (n=24). Although the results were non conclusive about the program's efficacy, the experimental group significantly improved their knowledge of the disease (p=0.008 d=0.79). Furthermore the qualitative analysis showed that children of patients were more positive than female spouses caregivers about the usefulness of the program. The findings of this research offer promising perspectives for this kind of interventions, particularly when individualized and centered on the needs of caregivers. This work allows for the understanding and analysis of specific methodological features to develop and evaluate caregivers' interventions.

La schizophrénie est considérée comme l'un des troubles psychiatriques les plus invalidants. L'une des principales raisons de ce fardeau élevé est qu'une grande partie des patients atteints de schizophrénie ne répondent pas adéquatement aux traitements pharmacologiques de première ligne et continueront de souffrir d’hallucinations auditives. La présence de celles-ci peut avoir un effet dévastateur sur le bien-être émotionnel des patients ainsi que sur leur qualité de vie. Les alternatives non-pharmacologiques (ex., Thérapie cognitivo-comportementale (TCC)) demeurent aussi limitées. Ainsi, pour plusieurs patients, les traitements actuellement recommandés ne sont pas suffisants. À cet égard, le traitement de la schizophrénie peut être perfectionné si, en plus du traitement des symptômes, l'accent thérapeutique est mis sur d’autres sphères importantes pour les patients (ex., améliorer l’estime de soi, réguler les émotions). Les efforts visant à accroître l'efficacité et les bénéfices des psychothérapies fondées sur des preuves ont mené à l'émergence d'interventions basées sur la réalité virtuelle (RV). Avec ces progrès technologiques, AVATAR Therapy et l’adaptation faite par notre équipe, la Thérapie assistée par la Réalité Virtuelle (TRV) (ou communément nommé la Thérapie Avatar (TA)), permettent aux patients d’entrer en dialogue en temps réel avec un avatar, animé entièrement par le thérapeute, qui représente leur voix la plus persécutrice. Cette approche, à la fois relationnelle et expérientielle, offre une occasion unique d’aider les patients à prendre le contrôle de leur voix. Cette thèse a pour objectif principal d’évaluer l’efficacité de cette psychothérapie basée sur la RV ainsi que les thèmes abordés durant et après la thérapie. Pour arriver à cette fin, divers objectifs ont été mis à l’avant : (i) résumer l'état des preuves sur l'efficacité des interventions basées sur la RV pour les troubles psychiatriques, (ii) évaluer l'efficacité de la TA/TRV par rapport à la TCC, (iii) illustrer l’efficacité de la thérapie à travers la perspective de patients ayant montré des effets bénéfiques, et (iv) explorer les thèmes émergeants ainsi que les processus thérapeutiques de la TA/TRV. Dans la première section, deux recensions des écritsdans diverses bases de données ont été effectuées pour examiner l’efficacité des psychothérapies basées sur la RV. Notre méta-revue (c’est-à-dire revue de méta-analyse) incluant 11 méta-analyses et 41 tailles d'effet a montré des résultats positifs de la RV dans le traitement des troubles psychiatriques, principalement des troubles anxieux. Les interventions basées sur la RV sont meilleures que le traitement usuel et montrent généralement des effets similaires par rapport aux approches fondées sur des preuves. Les résultats préliminaires suggèrent également que les effets de la RV se maintiennent dans le temps. Par contre, de nombreux symptômes et troubles psychiatriques qui peuvent être traités par des interventions utilisant RV n'ont pu être examinés par une analyse méta-analytique, en particulier les symptômes psychotiques (ex., hallucinations auditives) et les comportements liés à l'agressivité (ex., régulation émotionnelle). Ainsi, notre seconde revue a montré qu’il existe un nombre limité de paradigmes basés sur la RV pour traiter les individus atteints de troubles psychotiques et autres troubles mentaux à risque de comportements agressifs. Les études préliminaires dans des populations autres que la schizophrénie ont montré des réductions de la colère et de l'impulsivité, des améliorations des capacités de résolution des conflits ainsi que des niveaux d'empathie et des diminutions de l'agressivité. En ce qui a trait aux interventions basées sur la RV pour la schizophrénie, des réductions par rapport aux délires et aux hallucinations auditives ont été trouvées. Dans la seconde section, deux essais cliniques ont été menés pour évaluer l’efficacité de la TA/TRV seule en comparaison avec la TCC et en combinaison avec la TCC (TCC+TA/TRV). Notre essai randomisé comparant la TA/TRV à la TCC a compris 37 participants de plus de 18 ans entendant des voix persécutives et souffrant de schizophrénie résistante aux traitements dans chacun des groupes. Les résultats principaux ont montré que les deux interventions ont produit des améliorations significatives sur la sévérité des symptômes hallucinatoires avec des effets plus prononcés pour la TA/TRV. De plus, les résultats suggèrent une supériorité de la TA/TRV par rapport à la TCC sur les symptômes affectifs. La TA/TRV a également montré des effets positifs sur la qualité de vie. Les effets ont été maintenus à long terme, soit jusqu'à un an de suivi. Notre preuve de concept sur 10 patients ayant suivi la TCC de notre essai clinique comparatif qui souhaitaient continuer à obtenir des améliorations avec la TA/TRV a montré que les effets de la TCC+TA/TRV sur les symptômes dépressifs et les symptômes de la schizophrénie étaient plus larges que ceux trouvés pour l'une ou l'autre des interventions uniques. La troisième section a pour but de détailler les cas de 2 patients ayant suivi la TA/TRV. D’abord, nous avons décrit un partenariat entre un utilisateur de services en santé mentale et des chercheurs cliniciens en mettant en vedette M. X, le premier patient à suivre la thérapie. Nous avons ainsi montré l’apport de monsieur X quant à ses suggestions d’amélioration de la thérapie et ensuite en tant que notre pair aidant pour les futurs patients, dans son cheminement vers le rétablissement. Ensuite, nous avions rapporté le cas d'un patient atteint d’une schizophrénie ultra-résistante, soit M. Smith, qui n'a pas répondu à plusieurs traitements antipsychotiques, à la stimulation magnétique transcrânienne répétitive et à la thérapie par électrochocs avant de participer à notre essai. De plus, le patient a terminé notre TCC avant de se voir proposer notre TA/TRV. Cette dernière intervention a montré les effets les plus positifs. Or, ces deux cas ont montré que la thérapie a aidé non seulement à diminuer leurs symptômes, mais aussi à améliorer leur qualité de vie. La quatrième section a pour objectif d’explorer les thèmes émergents de la TA/TRV suite à des analyses de contenu. Ainsi, suite à une analyse qualitative découlant du discours spontané de 10 patients ayant bien répondu à la TA/TRV, quatre thèmes généraux ont émergé : impact de la thérapie sur les voix, relations interpersonnelles, bien-être psychologique et mode de vie. Cette analyse de contenu a permis d’identifier plusieurs sphères de vie qui sont davantage améliorées chez les patients ayant une schizophrénie résistante aux traitements à l’aide de la TA/TRV. Deux autres analyses qualitatives ont été conduites pour approfondir nos connaissances sur les processus thérapeutiques de la TA/TRV. Celles-ci ont permis de montrer que les patients répondent au propos de l’avatar en utilisant des mécanismes d'adaptation ou en exprimant des émotions, des croyances, des perceptions de soi ou des aspirations. Le discours de l'avatar a pu être catégorisé en techniques de confrontation (ex., provocation) et en techniques positives (ex., renforcement). Grâce à l'identification de changements mutuels dans l'interaction entre le patient et son avatar, un changement a été observé au fil des séances de la confrontation vers un dialogue constructif. L'affirmation de soi, les réponses émotionnelles et les stratégies de prévention semblaient être au cœur du processus thérapeutique, et celles-ci se produisent généralement en réponse à des techniques positives. Cette thèse contribue à la validation d’une nouvelle approche thérapeutique répondant à un besoin clinique fondamental. Ainsi, la TA/TRV met en lumière l'avenir des approches adaptées aux patients qui peuvent présenter des avantages par rapport aux traitements conventionnels. Ces types d’interventions holistiques utilisant la RV pourraient aussi présenter des avenues prometteuses dans plusieurs autres troubles psychiatriques. / Schizophrenia is considered one of the most debilitating psychiatric disorders. One of the main reasons for this high burden is that a large proportion of patients with schizophrenia do not respond adequately to first-line pharmacological treatments and will continue to suffer from auditory hallucinations. The presence of these symptoms can have a devastating effect on the emotional well-being of patients as well as their quality of life. Non-pharmacological alternatives (e.g., Cognitive Behavioral Therapy (CBT)) also remain limited. Thus, for many patients, the treatments currently recommended are not sufficient. In this regard, the treatment of schizophrenia may be improved if, in addition to the treatment of symptoms, therapeutic emphasis is placed on other areas of importance to patients (e.g., improving self-esteem, emotion regulation). Efforts to increase the effectiveness and benefits of evidence-based psychotherapies have led to the emergence of virtual reality (VR)-based interventions. With these technological advances, AVATAR Therapy and its related innovative form from our team, Virtual Reality Assisted Therapy (VRT) (or commonly Avatar Therapy (AT)), allow patients to enter a real-time dialogue with an avatar, animated entirely by the therapist, who represents their most persecutory voice. This approach, both relational and experiential, offers a unique opportunity to help patients take control of their voice. The main objective of this thesis is to evaluate the effectiveness of this psychotherapy based on VR as well as the themes addressed during and after the therapy. To achieve this end, various objectives have been put forward: (i) summarize the state of the evidence on the effectiveness of VR-based interventions for psychiatric disorders, (ii) assess the effectiveness of AT/VRT versus CBT, (iii) obtain the perspective of patients who have undergone AT/TRV, (iv) explore the therapeutic processes of AT/VRT. In the first section, two literature reviews in various databases were performed to examine the effectiveness of VR-based psychotherapies. Our meta-review including 11 meta-analyzes and 41 effect sizes showed positive results of VR in the treatment of psychiatric disorders, mainly anxiety disorders. VR-based interventions appear better than inactive controls and generally show similar effects compared to evidence-based approaches. Preliminary results also suggest that the effects of VR are sustained over time. On the other hand, many psychiatric symptoms and disorders that can be treated with interventions using VR have not been examined by a meta-analytical analysis, including psychotic symptoms (e.g., auditory hallucinations) and related behaviors. aggression (e.g., emotional regulation). Thus, our second review showed that there are a limited number of VR-based paradigms for treating individuals with psychotic disorders and other mental disorders at risk for aggressive behavior. Preliminary studies in populations other than schizophrenia have shown reductions in anger and impulsivity, improvements in conflict resolution skills as well as levels of empathy and decreases in aggression. Particularly related to VR interventions for schizophrenia, reductions in delusions and auditory hallucinations were found. In the second section, two clinical trials were conducted to evaluate the efficacy of AT/VRT alone in comparison with CBT and in combination with CBT (CBT+TA/VRT). Our randomized trial comparing AT/VRT to CBT included 37 participants over 18 years of age hearing persecutory voices and suffering from treatment-resistant schizophrenia in each group. The main results showed that the two interventions produced significant improvements in the severity of hallucinatory symptoms with more pronounced effects for AT/VRT. In addition, the results suggest that AT/VRT is superior to CBT on affective symptoms. AT/VRT has also shown positive effects on quality of life. The effects were maintained for up to one year of follow-up. Our proof of concept on 10 patients having followed CBT from our comparative clinical trial who wanted to continue to achieve improvements with AT/VRT showed that the effects of CBT+AT/VRT on depressive symptoms and symptoms of schizophrenia were broader than those found for either intervention alone. The third section details the cases of 2 patients who had followed AT/VRT. First, we described a partnership between a mental health service user and clinical researchers by featuring Mr. X, the first to follow therapy for his suggestions and our peer helper for future patients, on his journey to the recovery. Next, we reported the case of a patient with ultra-resistant schizophrenia, Mr. Smith, who failed to respond to multiple antipsychotic treatments, repetitive transcranial magnetic stimulation, and electroconvulsive therapy before participating in our trial. In addition, this patient completed our CBT before being offered AT/VRT. The latter intervention showed the most positive effects. These two cases showed that AT/VRT not only helped to decrease their symptoms, but also to improve their quality of life. The fourth section aimed to explore emerging themes of AT/VRT following content analyses. Thus, following a qualitative analysis resulting from the spontaneous speech of 10 patients who responded well to AT/VRT, four general themes emerged: impact of therapy on voices, interpersonal relationships, psychological well-being and lifestyle. This content analysis identified several areas of life that are further improved in patients with treatment resistant schizophrenia after having followed AT/VRT. Two other qualitative analyses were carried out to deepen our knowledge of the therapeutic processes of AT/VRT. These have shown that patients respond to the avatar's words by using a coping mechanism or by expressing emotions, beliefs, self-perceptions or aspirations. The avatar's discourse could be categorized into confrontational techniques (e.g., provocation) and positive techniques (e.g., reinforcement). With the identification of mutual changes in the interaction between the patient and their avatar, a shift was observed over therapy sessions from confrontation towards a constructive dialogue. Assertiveness, emotional responses, and prevention strategies seemed to be central to the therapeutic process, and these usually occurred in response to positive techniques. This thesis contributes to the validation of a new therapeutic approach responding to a fundamental clinical need. Thus, AT/VRT shines a light on the future of patient-oriented approaches that may have advantages over conventional treatments. These types of holistic interventions using VR may have notable applications in several other psychiatric disorders.

Pain during sexual intercourse, now classified under the single term of genito-pelvic pain/penetration disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), would affect up to 34% of young women and 45% of older women. Provoked vestibulodynia, a chronic pain elicited via pressure to the vulvar vestibule or attempted vaginal penetration, is the most common form of pain during intercourse. Controlled studies have shown that provoked vestibulodynia has multiple deleterious physical, psychological, sexual and relational impacts and thus greatly affects women’s quality of life, as well as their partners’. Provoked vestibulodynia occurs in the very intimate context of sexual intercourse. In that context, women’s self-concept could be negatively affected. Moreover, research among couples with provoked vestibulodynia has demonstrated the role of interpersonal factors in the modulation of women’s pain and associated consequences for both partners. Considering the documented efficacy of cognitive-behavioural therapy for chronic pain, including provoked vestibulodynia, and the importance of the relational context for this condition, a new cognitive-behavioural couple therapy has been developed by our team. It is the first treatment to take into account the interpersonal context of provoked vestibulodynia. Furthermore, we lack empirical evidence on mediators of change of cognitive-behavioural therapy for provoked vestibulodynia and on positive psychological factors that could foster better adjustment for women and their partners. The objective of this thesis was to use a dyadic perspective to examine the role of self-compassion in the adjustment of couples coping with provoked vestibulodynia, as well as the roles of both partners’ pain self-efficacy and pain catastrophizing as mediators of change in cognitive-behavioural couple therapy. The first study examined the associations between self-compassion of women with provoked vestibulodynia and their partners and their depression, anxiety, sexual distress and relational satisfaction as well as women’s pain intensity during intercourse. Forty-eight couples with provoked vestibulodynia completed self-report questionnaires. For both women and their partners, higher levels of self-compassion were associated with their own lower anxiety and depression. When partners reported higher levels of self-compassion, they were more satisfied with their relationship, and both partners and women reported lower sexual distress. No significant association was found for pain during intercourse. The second article examined pain self-efficacy and catastrophizing as mediators of therapeutic change regarding pain, sexual distress and sexual function in cognitive-behavioural couple therapy for provoked vestibulodynia. Because cognitive-behavioural couple therapy did not improve significantly more pain self-efficacy relative to lidocaine treatment, this variable was not included in subsequent mediation models. In women with provoked vestibulodynia, greater decreases in pain catastrophizing in cognitive-behavioural couple therapy, as compared to the lidocaine control condition, mediated reductions in pain intensity and sexual distress as well as improvement of sexual function. In partners, greater decreases in pain catastrophizing in cognitive-behavioural couple therapy, as compared to the lidocaine control condition, mediated reductions in sexual distress and improvement of sexual function. Partners’ pain catastrophizing reductions also mediated women’s decrease in sexual distress. Implications of results, as well as theoretical, methodological and clinical contributions of the thesis are discussed. / Les problèmes de douleur durant les relations sexuelles, maintenant désignés par le terme « douleur génito-pelvienne » dans le Manuel diagnostique et statistique des troubles mentaux (DSM-5), toucheraient jusqu’à 34% des jeunes femmes et 45% des femmes plus âgées. La cause la plus fréquente de douleur génito-pelvienne serait la vestibulodynie provoquée (VP). Les études contrôlées indiquent que la VP a des conséquences négatives multiples, physiques, psychologiques, sexuelles et relationnelles, et hypothèque donc grandement la qualité de vie des femmes qui en souffrent, ainsi que celle de leurs partenaires. Une particularité de ce problème de douleur chronique est le contexte dans lequel il survient, soit celui des relations intimes. Dans ce contexte, l'image que les femmes souffrant de VP ont d'elles-mêmes en tant que partenaires sexuelles serait affectée. De plus, la recherche a démontré l’influence des facteurs interpersonnels sur l’intensité de la douleur et les conséquences psychologiques et sexuelles associées. Considérant l’efficacité documentée des thérapies cognitivo-comportementales (TCC) pour la douleur chronique, incluant la VP et l’importance du contexte relationnel de cette problématique, une nouvelle TCC de gestion de la douleur a été développée pour les couples. Ce traitement vient combler une lacune importante du domaine puisqu’aucun autre traitement à ce jour ne tient compte de l’influence des facteurs interpersonnels. Par ailleurs, le manque de connaissance des mécanismes de changement sous-tendant l’efficacité des traitements psychologiques pour la VP ainsi que le peu d’études sur les facteurs psychologiques qui joueraient un rôle protecteur chez les femmes souffrant de VP sont d’autres limites du domaine. Afin de pallier ces lacunes, l’objectif de la thèse était d’examiner dans une perspective dyadique le rôle de l’auto-compassion dans l’ajustement de couples faisant face à la VP, de même que le rôle du catastrophisme et l’auto-efficacité comme médiateurs de changement dans le cadre d’un essai clinique randomisé évaluant l’efficacité de la thérapie cognitive-comportementale de couple (TCCC). Le premier article de la thèse visait à examiner les liens entre l’auto-compassion et l’ajustement psychologique et sexuel des femmes souffrant de VP et de leurs partenaires. Quarante-huit couples ont complété des questionnaires auto-rapportés. Les analyses ont montré que plus d’auto-compassion chez les femmes souffrant de VP était associée à moins de symptômes dépressifs et anxieux chez celles-ci. Plus d’auto-compassion chez les partenaires était aussi associée à moins de symptômes dépressifs et anxieux de même que plus de satisfaction relationnelle chez ceux-ci. De plus, des niveaux plus élevés d’auto-compassion chez les partenaires étaient aussi associés à moins de détresse sexuelle pour eux et pour l’autre membre du couple, soit la femme souffrant de VP. Aucune association avec l’intensité de la douleur n’était significative. Dans le deuxième article de la thèse, l’auto-efficacité et le catastrophisme ont été examinés en tant que médiateurs de changement thérapeutique au cours de la TCCC, comparée à un traitement médical, la lidocaïne topique. Puisque la TCCC n’améliorait pas l’auto-efficacité significativement plus que le traitement de lidocaïne, cette variable n’a pas été incluse dans les modèles de médiation. La TCCC, en comparaison avec le groupe contrôle de lidocaïne, diminuait significativement la douleur, la détresse sexuelle et la fonction sexuelle des femmes via la plus grande diminution de leurs propres niveaux de catastrophisme, en comparaison au groupe contrôle de lidocaïne. La plus grande diminution du catastrophisme chez les partenaires, en comparaison au groupe contrôle, expliquait également les améliorations quant à leur propre détresse et fonction sexuelle. Enfin, la plus grande diminution du catastrophisme chez les partenaires expliquait la diminution de la détresse sexuelle des femmes dans le groupe TCCC, en comparaison au groupe contrôle. Les implications de ces résultats et les contributions théoriques, cliniques et méthodologiques de la thèse sont discutées.